Showing results (311-320 of 355) with videos related to

Sort By:
Pageof 36
Oncology Reports|May 21, 2011
P53 gene alterations in differentiated thyroid cancersM Herrmann, D Baunoch, M Maliarik, et al.
Clinical Breast Cancer|May 31, 2015
Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is NewEunpi Cho, Ann K Schwemm, Lena M Rubinstein, et al.
Nuclear Medicine and Biology|October 9, 2007
Challenges in clinical studies with multiple imaging probesKenneth A Krohn, Finbarr O'Sullivan, John Crowley, et al.
Breast Cancer Research and Treatment|February 3, 2007
Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)Jennifer M Specht, Stephen L Tam, Brenda F Kurland, et al.
Journal of the American Chemical Society|June 13, 2025
Isomerization of Poly(ethylene glycol): A Strategy for the Evasion of Anti-PEG Antibody RecognitionPhilip Dreier, Rebecca Matthes, Fabian Fuß, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2007
Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313)Hannah M Linden, Charles M Haskell, Stephanie J Green, et al.
Research Square|February 5, 2024
Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trialsMark Muzi, Lanell M Peterson, Jennifer M Specht, et al.
EJNMMI Research|March 27, 2024
Repeatability of 18F-FDG uptake in metastatic bone lesions of breast cancer patients and implications for accrual to clinical trialsMark Muzi, Lanell M Peterson, Jennifer M Specht, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 27, 2018
Test-Retest Reproducibility of 18F-FDG PET/CT Uptake in Cancer Patients Within a Qualified and Calibrated Local NetworkBrenda F Kurland, Lanell M Peterson, Andrew T Shields, et al.
Molecular Imaging and Biology|October 17, 2018
Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC)Lanell M Peterson, Brenda F Kurland, Erin K Schubert, et al.
Pageof 36